Artimplant: Start-Up Of US-Based Study For Treatment Of Rotator Cuff Tears With Artelon(R) Tissue Reinforcement

Main Category: Bones / Orthopaedics
Also Included In: Clinical Trials / Drug Trials;  Pain / Anesthetics
Article Date: 27 Oct 2008 - 11:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Artimplant (STO:ARTIB) has agreed with Tulsa Bone & Joint Associates, Tulsa, Oklahoma to execute a clinical study on patients with soft tissue injuries in the rotator cuff.

The study comprises 25 patients with one year follow up and is estimated to be completed the first quarter of 2010. Dr. Thomas Marberry has operated on their first patient with Artelon® Tissue Reinforcement.

Dr. Thomas Marberry says;

"Tears of the rotator cuff tendons are one of the most common causes of shoulder pain and disability in the upper extremity. In our study we will treat patients with large or massive rotator cuff tears. I am excited with the benefit that Artelon® Tissue Reinforcement may provide to my patients. The objective with our study is to scientifically confirm the positive clinical experience we have with the product so far."

Hans Rosen, CEO Artimplant says;

"We are very enthusiastic about the cooperation with Dr. Marberry and his colleagues at Tulsa Bone & Joint Associates. This study is an important step forward in strengthening the scientific and commercial basis for the use of Artelon® in rotator cuff tears."

About Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral surgery and veterinary medical applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on October 27, 2008 at 08:45 AM (GMT+1).

Source
Hans Rosen, CEO
Artimplant